Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMEA NASDAQ:PTGX NASDAQ:SPPI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMEABiomea Fusion$1.93-1.0%$1.89$1.29▼$13.07$73.27M-0.131.17 million shs1.02 million shsPTGXProtagonist Therapeutics$52.83+1.0%$49.88$32.50▼$60.60$3.24B2.26840,520 shs654,941 shsSPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/AThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMEABiomea Fusion-1.03%+16.69%-23.72%+10.29%-59.37%PTGXProtagonist Therapeutics+1.03%+3.18%-6.28%+23.96%+51.90%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBMEABiomea Fusion2.621 of 5 stars3.61.00.00.02.52.50.6PTGXProtagonist Therapeutics2.5218 of 5 stars3.51.00.00.03.72.50.0SPPISpectrum Pharmaceuticals0.5536 of 5 stars0.00.00.04.70.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMEABiomea Fusion 3.18Buy$21.401,008.81% UpsidePTGXProtagonist Therapeutics 3.00Buy$66.1025.12% UpsideSPPISpectrum Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BMEA, SPPI, and PTGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.006/17/2025PTGXProtagonist TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$72.006/13/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.006/3/2025BMEABiomea FusionPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$7.006/3/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.006/2/2025BMEABiomea FusionPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/19/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/15/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.005/6/2025BMEABiomea FusionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $18.005/6/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMEABiomea FusionN/AN/AN/AN/A$1.42 per shareN/APTGXProtagonist Therapeutics$434.43M7.54$4.56 per share11.58$11.33 per share4.66SPPISpectrum Pharmaceuticals$10.11M20.91N/AN/A$0.15 per share6.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMEABiomea Fusion-$138.43M-$3.55N/AN/AN/AN/A-197.71%-134.84%7/30/2025 (Estimated)PTGXProtagonist Therapeutics$275.19M$0.7570.44N/AN/A27.04%9.22%8.31%8/5/2025 (Estimated)SPPISpectrum Pharmaceuticals-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/ALatest BMEA, SPPI, and PTGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025PTGXProtagonist Therapeutics-$0.53N/AN/AN/A$8.32 millionN/A7/30/2025Q2 2025BMEABiomea Fusion-$0.64N/AN/AN/AN/AN/A5/6/2025Q1 2025PTGXProtagonist Therapeutics-$0.50-$0.19+$0.31-$0.19$30.44 million$28.32 million5/5/2025Q1 2025BMEABiomea Fusion-$0.84-$0.80+$0.04-$0.80N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMEABiomea FusionN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMEABiomea FusionN/A2.252.25PTGXProtagonist TherapeuticsN/A17.2517.26SPPISpectrum PharmaceuticalsN/A2.712.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMEABiomea Fusion96.72%PTGXProtagonist Therapeutics98.63%SPPISpectrum Pharmaceuticals21.67%Insider OwnershipCompanyInsider OwnershipBMEABiomea Fusion18.42%PTGXProtagonist Therapeutics4.90%SPPISpectrum Pharmaceuticals2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMEABiomea Fusion5037.57 million30.65 millionOptionablePTGXProtagonist Therapeutics12061.98 million58.95 millionOptionableSPPISpectrum Pharmaceuticals86205.25 million199.70 millionOptionableBMEA, SPPI, and PTGX HeadlinesRecent News About These CompaniesPneumagen Announces Peer-Reviewed Publication of Positive Phase II Study Data Highlighting the Potential of Neumifil, a Novel Broad-Spectrum AntiviralJuly 2, 2025 | globenewswire.comIDMC Provides Positive Recommendation for Bio-Thera Solution's BAT4406F (ADCC-Enhanced Anti-CD20 mAb) in Neuromyelitis Optica Spectrum Disorder Based on Interim Analysis of Pivotal Phase II/III TrialJuly 2, 2025 | prnewswire.comThere is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug CandidateJuly 1, 2025 | accessnewswire.comAOsivax Announces Last Patient Last Visit in Phase 2a Trial Evaluating a Booster Dose of Broad-Spectrum Influenza Vaccine OVX836 s releaseJune 5, 2025 | globenewswire.comBroad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of CongoMay 8, 2025 | accessnewswire.comABio-Thera Solutions Publishes Phase I Clinical Study Results for BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum DisordersJanuary 14, 2025 | prnewswire.comNon-Hodgkin’s Lymphoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and BarriersNovember 4, 2024 | theglobeandmail.comSpectrum Thin Films, Inc.October 31, 2024 | optics.orgOIndia – Key Considerations For Patenting Nutraceuticals/Dietary Supplements.October 10, 2024 | conventuslaw.comCQylur Awarded SBIR Phase II Contract for a Tactical AI Spectrum Classifier Systems (TASCS)October 2, 2024 | globenewswire.comNanoViricides prepares for Phase II trial of broad-spectrum antiviral NV-387August 19, 2024 | proactiveinvestors.comGPC Biotech Announces Granting of European Patent Related to Satraplatin for Treating Tumors Resistant or Refractory to TaxanesAugust 19, 2024 | br.advfn.comGlobal AL Amyloidosis Therapeutics Market Set for Remarkable Growth, Projected to Reach USD 4.56 Billion by 2033July 31, 2024 | fmiblog.comFCompany History - Paam Drugs and PharmaceuticalsJuly 19, 2024 | moneycontrol.comSTALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in BiomedicinesJune 27, 2024 | globenewswire.comOsivax Completes Enrollment for Phase 1 Trial with Broad-Spectrum Sarbecovirus Vaccine Candidate, OVX033June 25, 2024 | businesswire.comPneumagen Presents Positive Phase 2 Influenza Human Challenge Study data on Neumifil, its Broad-Spectrum Antiviral Drug, at the American Thoracic Society (ATS) 2024 ConferenceMay 23, 2024 | globenewswire.comPneumagen to Present Phase 2 Clinical Data on Neumifil, its Broad-Spectrum Antiviral, Intranasal Drug for Viral Respiratory Tract Infections, at ATS 2024May 2, 2024 | globenewswire.comSpectrum Pharmaceuticals gets grant for crystalline form of quinazoline compound and hydrochloride saltsApril 24, 2024 | pharmaceutical-technology.comPAssertio Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - ASRTFebruary 21, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBMEA, SPPI, and PTGX Company DescriptionsBiomea Fusion NASDAQ:BMEA$1.93 -0.02 (-1.03%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$1.90 -0.03 (-1.81%) As of 08:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.Protagonist Therapeutics NASDAQ:PTGX$52.83 +0.54 (+1.03%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$51.00 -1.83 (-3.46%) As of 09:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Spectrum Pharmaceuticals NASDAQ:SPPISpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
